从样蛋白到突触功能障碍:对阿尔茨海默病的生物标志物驱动的洞察
Luisa Agnello1, Caterina Maria Gambino1,2, Anna Maria Ciaccio3
1Institute of Clinical Biochemistry, Clinical Molecular Medicine, and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences, and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy.
Current issues in molecular biology
|August 27, 2025
概括
这种疾病
科学领域:
- 神经退行性疾病
- 生物标志物发现
- 精准医学
背景情况:
- 阿尔茨海默病 (AD) 是神经退行的主要原因,由于预期寿命增加,其发病率正在上升.
- 目前的阿尔茨海默病诊断依赖于临床评估和神经影像,因此需要改进早期检测方法.
- 生物标志物改变了AD的评估,为疾病的分期和监测提供了客观的措施.
研究的目的:
- 审查阿尔茨海默病 (AD) 的已知和新出现的生物标志物.
- 突出生物标志物在早期阿尔茨海默病诊断和患者分层中的作用.
- 讨论新生物标志物在阿尔茨海默病的精准医学方面的潜力.
主要方法:
- 传统的AD生物标志物 (Aβ42/Aβ40,tau蛋白,NfL) 的审查.
- 探索包含新生物标志物 (例如SNAP-25,YKL-40,TREM2) 的ATN(X) 模型
- 在各种生物流体 (CSF,血,外体) 中检测生物标志物的讨论.
主要成果:
- 已确定的生物标志物 (Aβ42/Aβ40,p-Tau,t-tau,NfL) 对于AD分期至关重要.
- 该ATN (X) 模型扩展了生物标志物分类,并增加了有前途的新标志物.
- 进步使得在等离子体和外体中检测生物标志物的侵入性降低.
结论:
- 生物标志物正在彻底改变阿尔茨海默病的诊断和治疗.
- 新兴的生物标志物为早期检测和个性化治疗策略提供了更大的潜力.
- 转向可访问的生物流体分析有望得到更广泛的临床应用.
相关概念视频
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
03:03Amyloid Fibrils
9.8K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.8K